We are live on ! Find out more
BSTC

BioSpecifics Technologies Corp.
BSTC

Delisted

BSTC was delisted on the 1st of December, 2020.

38 hedge funds and large institutions have $40.8M invested in BioSpecifics Technologies Corp. in 2013 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 16 increasing their positions, 12 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 12

3% more capital invested

Capital invested by funds: $39.8M → $40.8M (+$1.03M)

7% less funds holding

Funds holding: 4138 (-3)

43% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 7

Holders
38
Holders Change
-3
Holders Change %
-7.32%
% of All Funds
1.1%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
4
Increased
16
Reduced
12
Closed
7
Calls
Puts
Net Calls
Net Calls Change

BSTC Hedge Fund Activity: Q4 2013 in Review

38 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in BioSpecifics Technologies Corp. (BSTC) for Q4 2013, worth a combined $40.8M — up 2.6% from $39.8M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of BSTC and 4 opened new positions — a net loss of 3 holders — while 12 trimmed existing stakes and 16 added.

The largest buyer was Northpointe Capital, adding an estimated $837K. The largest seller was BlackRock Advisors, cutting an estimated $1.86M.

  • 38 institutional investors held BioSpecifics Technologies Corp. (BSTC) as of Q4 2013, down from 41 in Q3 2013.
  • Funds reported $40.8M of BioSpecifics Technologies Corp. stock for Q4 2013, up 2.6% quarter-over-quarter.
  • 4 funds opened new BioSpecifics Technologies Corp. positions in Q4 2013 and 7 closed out, a net change of -3 holders.
  • The largest BioSpecifics Technologies Corp. buyer in Q4 2013 was Northpointe Capital, an estimated $837K added.
  • The largest BioSpecifics Technologies Corp. seller in Q4 2013 was BlackRock Advisors, an estimated $1.86M sold.

Based on aggregated 13F filings for Q4 2013.